Lipocine and Pharmalink Partner to Supply and Distribution of Oral Testosterone Therapy in GCC

• Lipocine Inc. has signed an exclusive supply and distribution deal with Pharmalink for TLANDO in the Gulf Cooperation Council (GCC) countries.

• The agreement involves the commercialisation of TLANDO, an oral testosterone therapy, in six countries including Saudi Arabia and the UAE.

Lipocine Inc., a biopharmaceutical company specialising in oral drug delivery technologies, has entered into an exclusive supply and distribution agreement with Pharmalink to commercialise TLANDO, its oral testosterone replacement therapy, across the Gulf Cooperation Council (GCC) region. The agreement covers six countries: Saudi Arabia, Kuwait, the United Arab Emirates (UAE), Qatar, Bahrain, and Oman.

Under the terms of the agreement, Lipocine will provide TLANDO to Pharmalink after receiving Marketing Authorizations (MA) in individual GCC countries. In return, Lipocine has received an upfront payment and will supply the product at an agreed transfer price. Pharmalink will manage the promotion, distribution, and sales of TLANDO across the region.

“We are very pleased to partner with Pharmalink to bring TLANDO to the GCC region,” said Dr. Mahesh Patel, President and CEO of Lipocine. “This agreement aligns with our global strategy to expand TLANDO’s availability and make it more accessible.”

The partnership is expected to help TLANDO, which provides a convenient oral option for testosterone replacement, gain a foothold in the growing markets of the Middle East. Pharmalink’s extensive network and expertise within the region make them a key partner for this initiative.

By ensuring a smooth supply chain and efficient distribution, the collaboration aims to support the adoption and growth of TLANDO, offering a new option for patients in need of testosterone replacement therapy.